stockrowBruker Corporation
BRKR Healthcare Medical Devices
Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.
- Revenue
- +1.57%
- EPS
- −75.4%
- Free cash flow
- +278.7%
- Total debt
- −14.7%
Quarter to September 2026, against a year earlier
Follow BRKR
Alert me
Bruker Corporation (BRKR) Return on assets
Bruker Corporation's return on assets over the twelve months to 30 September 2026 was −2.73%, down 2.4 percentage points from fiscal 2025 (−0.37%). Over the past ten years it has ranged from −0.37% (fiscal 2025) to 10.9% (fiscal 2023) — the current reading is the lowest in ten years. That is above the Medical Devices industry median of −17.3% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −0.37% | (2.62) |
| FY2024 | 2.25% | (8.62) |
| FY2023 | 10.9% | 2.70 |
| FY2022 | 8.17% | (0.10) |
| FY2021 | 8.27% | 2.85 |
| FY2020 | 5.42% | (2.63) |
| FY2019 | 8.05% | (0.77) |
| FY2018 | 8.82% | 4.64 |
| FY2017 | 4.18% | (4.50) |
| FY2016 | 8.68% | 3.03 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| PODD Insulet Corporation compare | 13.3% |
| GMED Globus Medical, Inc. compare | 10.5% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 9.99% |
| BIO Bio-Rad Laboratories, Inc. compare | 9.99% |
| PEN Penumbra, Inc. compare | 8.33% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| BRKR Bruker Corporation | −2.73% |
| TXG 10x Genomics compare | −7.47% |
| GKOS Glaukos Corporation compare | −17.2% |
| Medical Devices industry median | −17.3% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on BRKR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement